SETDB1-IN-1
SETDB1-IN-1 is a SETDB1 inhibitor with an IC50 of 16 μM. SETDB1-IN-1 inhibits histone methyltransferase) activity via SAM-competitive and peptide-dependent mechanisms. SETDB1-IN-1 is applicable to research related to melanoma, lung cancer, liver cancer, breast cancer and prostate cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2585194-96-1
- 分子式: C12H18ClFN6O2S
- 分子量:364.83
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
Histone Methyltransferase アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
体外実験
SETDB1-IN-1 (Compound 7) exhibits limited selectivity in a panel of 16 purified methyltransferases, and shows potent inhibitory activity against SETDB1, SUV39H1, SUV39H2, PRMT7 and PRMT1[1].
SETDB1-IN-1 is a peptide-dependent, SAM-competitive inhibitor of purified recombinant SETDB1 (570-1291)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
化学情報
-
CAS 番号 2585194-96-1
-
分子量 364.83
-
分子式 C12H18ClFN6O2S
-
SMILES
NC1=NC=NC2=C1N=CN2[C@H]3[C@H](F)[C@H](O)[C@@H](CSCCN)O3.Cl
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)